167 related articles for article (PubMed ID: 34024922)
1. Existence of Notoriety Bias in FDA Adverse Event Reporting System Database and Its Impact on Signal Strength.
Neha R; Subeesh V; Beulah E; Gouri N; Maheswari E
Hosp Pharm; 2021 Jun; 56(3):152-158. PubMed ID: 34024922
[No Abstract] [Full Text] [Related]
2. Impact of safety alerts on measures of disproportionality in spontaneous reporting databases: the notoriety bias.
Pariente A; Gregoire F; Fourrier-Reglat A; Haramburu F; Moore N
Drug Saf; 2007; 30(10):891-8. PubMed ID: 17867726
[TBL] [Abstract][Full Text] [Related]
3. Stimulated reporting: the impact of US food and drug administration-issued alerts on the adverse event reporting system (FAERS).
Hoffman KB; Demakas AR; Dimbil M; Tatonetti NP; Erdman CB
Drug Saf; 2014 Nov; 37(11):971-80. PubMed ID: 25255848
[TBL] [Abstract][Full Text] [Related]
4. Pantoprazole associated dyspepsia hypocalcemia and hyponatremia: A disproportionality analysis in FDA adverse event reporting system (FAERS) database.
Nair HP; Kulkarni AR; Eswaran M; Subeesh V
Arab J Gastroenterol; 2023 Feb; 24(1):1-4. PubMed ID: 36725376
[TBL] [Abstract][Full Text] [Related]
5. Postmarketing safety of anaplastic lymphoma kinase (ALK) inhibitors: an analysis of the FDA Adverse Event Reporting System (FAERS).
Omar NE; Fahmy Soliman AI; Eshra M; Saeed T; Hamad A; Abou-Ali A
ESMO Open; 2021 Dec; 6(6):100315. PubMed ID: 34864500
[TBL] [Abstract][Full Text] [Related]
6. Drug-induced torsades de pointes: Disproportionality analysis of the United States Food and Drug Administration adverse event reporting system.
Wu Z; Zhou P; He N; Zhai S
Front Cardiovasc Med; 2022; 9():966331. PubMed ID: 36352852
[TBL] [Abstract][Full Text] [Related]
7. Vemurafenib Induced Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS): A Disproportionality Analysis in FAERS Database.
Neha R; Beulah E; Anusha B; Vasista S; Stephy C; Subeesh V
Curr Rev Clin Exp Pharmacol; 2021; 16(2):168-173. PubMed ID: 32598268
[TBL] [Abstract][Full Text] [Related]
8. Post-marketing safety of immunomodulatory drugs in multiple myeloma: A pharmacovigilance investigation based on the FDA adverse event reporting system.
Jiang T; Su H; Li Y; Wu Y; Ming Y; Li C; Fu R; Feng L; Li Z; Li L; Ni R; Liu Y
Front Pharmacol; 2022; 13():989032. PubMed ID: 36532784
[No Abstract] [Full Text] [Related]
9. The association of pancreatitis with antidiabetic drug use: gaining insight through the FDA pharmacovigilance database.
Raschi E; Piccinni C; Poluzzi E; Marchesini G; De Ponti F
Acta Diabetol; 2013 Aug; 50(4):569-77. PubMed ID: 22008948
[TBL] [Abstract][Full Text] [Related]
10. Profiling cumulative proportional reporting ratios of drug-induced liver injury in the FDA Adverse Event Reporting System (FAERS) database.
Brinker AD; Lyndly J; Tonning J; Moeny D; Levine JG; Avigan MI
Drug Saf; 2013 Dec; 36(12):1169-78. PubMed ID: 24178291
[TBL] [Abstract][Full Text] [Related]
11. The Weber effect and the United States Food and Drug Administration's Adverse Event Reporting System (FAERS): analysis of sixty-two drugs approved from 2006 to 2010.
Hoffman KB; Dimbil M; Erdman CB; Tatonetti NP; Overstreet BM
Drug Saf; 2014 Apr; 37(4):283-94. PubMed ID: 24643967
[TBL] [Abstract][Full Text] [Related]
12. Adverse Events Related to Off-Label Drugs Using Spontaneous Adverse Event Reporting Systems.
Han N; Oh JM; Kim IW
Ther Clin Risk Manag; 2021; 17():877-887. PubMed ID: 34456568
[TBL] [Abstract][Full Text] [Related]
13. Notoriety bias in a database of spontaneous reports: the example of osteonecrosis of the jaw under bisphosphonate therapy in the French national pharmacovigilance database.
de Boissieu P; Kanagaratnam L; Abou Taam M; Roux MP; Dramé M; Trenque T
Pharmacoepidemiol Drug Saf; 2014 Sep; 23(9):989-92. PubMed ID: 24737486
[TBL] [Abstract][Full Text] [Related]
14. Bisphosphonates and nonhealing femoral fractures: analysis of the FDA Adverse Event Reporting System (FAERS) and international safety efforts: a systematic review from the Research on Adverse Drug Events And Reports (RADAR) project.
Edwards BJ; Bunta AD; Lane J; Odvina C; Rao DS; Raisch DW; McKoy JM; Omar I; Belknap SM; Garg V; Hahr AJ; Samaras AT; Fisher MJ; West DP; Langman CB; Stern PH
J Bone Joint Surg Am; 2013 Feb; 95(4):297-307. PubMed ID: 23426763
[TBL] [Abstract][Full Text] [Related]
15. DPP-4 Inhibitors and Increased Reporting Odds of Bullous Pemphigoid: A Pharmacovigilance Study of the FDA Adverse Event Reporting System (FAERS) from 2006 to 2020.
Jedlowski PM; Jedlowski MF; Fazel MT
Am J Clin Dermatol; 2021 Nov; 22(6):891-900. PubMed ID: 34287770
[TBL] [Abstract][Full Text] [Related]
16. Drug-induced hypoglycemia: a disproportionality analysis of the FAERS database.
Li J; Wang Y; Yang X; Zhu H; Jiang Z
Expert Opin Drug Saf; 2023 Nov; ():1-7. PubMed ID: 37909653
[TBL] [Abstract][Full Text] [Related]
17. Novel Adverse Events of Iloperidone: A Disproportionality Analysis in US Food and Drug Administration Adverse Event Reporting System (FAERS) Database.
Subeesh V; Maheswari E; Singh H; Beulah TE; Swaroop AM
Curr Drug Saf; 2019; 14(1):21-26. PubMed ID: 30362421
[TBL] [Abstract][Full Text] [Related]
18. Hepatotoxicity reports in the FDA adverse event reporting system database: A comparison of drugs that cause injury
Rana P; Aleo MD; Wen X; Kogut S
Acta Pharm Sin B; 2021 Dec; 11(12):3857-3868. PubMed ID: 35024312
[TBL] [Abstract][Full Text] [Related]
19. Research on Beers Criteria and STOPP/START Criteria based on the FDA FAERS database.
Shao Q; Xu Y; Li M; Chu X; Liu W
Eur J Clin Pharmacol; 2021 Aug; 77(8):1147-1156. PubMed ID: 34170370
[TBL] [Abstract][Full Text] [Related]
20. US Food and Drug Administration Safety Advisories and Reporting to the Adverse Event Reporting System (FAERS).
Moore TJ; Morrow RL; Dormuth CR; Mintzes B
Pharmaceut Med; 2020 Apr; 34(2):135-140. PubMed ID: 32180152
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
